Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302274 · ClinicalTrials.gov registry record
Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 209
- Enrollment target
NCT02302274: Completed study, sponsored by NYU Langone Health.
NCT02302274 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 209 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02302274 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 209 participants
- Enrollment target
Study Summary
The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy it proposes to apply this test to early ARVC cases in order to evaluate if ECG changes similar to those seen in Brugada Syndrome could be unmasked by flecainide iv.
Primary Outcome
conversion from type 2/3 Brugada ECG to diagnostic type 1 ECG
Interventions
- DRUG flecainide iv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 209 participants |
| Start Date | 2010-07-01 |
| Est. Completion | 2017-07-26 |
What the finished NCT02302274 record still lists
NCT02302274 is an observational study that tracks outcomes without assigning an intervention. The registered 209 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which flecainide iv is the first listed.
NCT02302274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02302274 about?
NCT02302274 is a clinical study titled "Diagnostic Value and Safety of Flecainide Infusion Test in Brugada Syndrome". The study aims to use flecainide infusion test as diagnostic test to unmask concealed Brugada Syndrome cases. It proposes to assess the safety profile of this test in US patients and its higher sensitivity when compared to procainamide infusion (the conventional drug used in the USA). As a substudy ...
What is the current status of trial NCT02302274?
This trial is currently completed. The enrollment target is 209 participants. The study started on 2010-07-01. Estimated completion is 2017-07-26.
What interventions are being tested in trial NCT02302274?
The interventions under investigation include: flecainide iv (DRUG).
Who is sponsoring clinical trial NCT02302274?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04742634 · 209 participants · Phase 1
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
- NCT07214688 · 209 participants · Phase 2
Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI